Tumor regression grade after neoadjuvant chemotherapy in patients with locally advanced gastric cancer treated with modern chemotherapy (FLOT): Experience in patients in Guatemala. This is an ASCO ...
Enrollment insights in the synchronous mRCC population: An update from the ongoing ADAPT* phase 3 study experience. Background: Pazopanib is an oral, selective, multikinase inhibitor of VEGF receptors ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results